About the Company
Losmapimod (GW856553X) is an investigational drug being developed by Fulcrum Therapeutics for the treatment of facioscapulohumeral muscular dystrophy (FSHD); a phase III clinical trial is pending approval. Losmapimod selectively inhibits enzymes p38α/β mitogen-activated protein kinases (MAPKs), which are modulators of DUX4 expression and mediators of inflammation.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FULC News
Fulcrum Therapeutics, Inc. (FULC)
CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company ...
Fulcrum Therapeutics Stock (NASDAQ:FULC), Analyst Ratings, Price Targets, Predictions
$9.54 109.64% HC Wainwright & Co.
Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate
Fulcrum Therapeutics, Inc. price-consensus-chart | Fulcrum Therapeutics, Inc. Quote Fulcrum currently carries a Zacks Rank #3 (Hold). In the past 90 days, the Zacks Consensus Estimate forANI ...
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company ...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the ...
FULC Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high ...
Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the ...
Fulcrum Therapeutics Inc FULC
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Fulcrum Therapeutics Inc (FULC)
On Wednesday, RBC Capital initiated coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a rating of Outperform and a price target of $14.00. The firm views Fulcrum as a ...
Fulcrum Therapeutics Inc (FULC)
Point72 Asset Management increased stake in Tricida, Inc. ByInvesting.com • Apr 02, 2021 On the 23rd of March, Point72 Asset Management bought 1.3 million Tricida , Inc. (NASDAQ:TCDA ...
Loading the latest forecasts...